|
Report Date : |
24.07.2012 |
IDENTIFICATION DETAILS
|
Name : |
SAVA MEDICA LIMITED (w.e.f.22.04.2010) |
|
|
|
|
Formerly Known
As : |
SAVA MEDICA PRIVATE LIMITED |
|
|
|
|
Registered Office
: |
Sava House, 3rd Floor, |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as
on) : |
31.03.2011 |
|
|
|
|
Date of
Incorporation : |
10.02.2010 |
|
|
|
|
Com. Reg. No.: |
25-135514 |
|
|
|
|
Capital
Investment / Paid-up Capital : |
Rs.54.100 Millions |
|
|
|
|
CIN No.: [Company Identification
No.] |
U74999PN2010PLC135514 |
|
|
|
|
TAN No.: [Tax Deduction &
Collection Account No.] |
PNES27962E |
|
|
|
|
Legal Form : |
A Closely Held Public Limited Liability Company |
|
|
|
|
Line of Business
: |
Manufacturer of Pharmaceutical products,
ayurvedic medicines, allopathic medicines. |
|
|
|
|
No. of Employees
: |
Not Divulged |
RATING & COMMENTS
|
MIRA’s Rating : |
B (26) |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Maximum Credit Limit : |
USD 220000 |
|
|
|
|
Status : |
Moderate |
|
|
|
|
Payment Behaviour : |
Slow but correct |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject is a relatively new company having moderate track.
Profitability appears to be low. Trade relations are reported as fair. Business is active. Payments are
reported to be slow but correct. The company can be considered for business dealings with some caution. |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
RBI DEFAILTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter
in the publicly available RBI Defaulters’ list.
EPF (Employee Provident Fund) DEFAILTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter
in the publicly available EPF (Employee Provident Fund) Defaulters’ list as of
31-03-2012.
INFORMATION DENIED BY
|
Name : |
Mr. Adam Patel |
|
Designation : |
Manager in Finance and Accountant |
|
Contact No.: |
91-20-30516100 |
|
Date : |
23.07.2012 |
LOCATIONS
|
Registered Office : |
Sava House, 3rd Floor, Lalwani Plaza, Wing B, Sakorenagar CHS,
Off New Airport Road, Viman Nagar, Pune – 411014, Maharashtra |
|
Tel. No.: |
91-20-30516100 |
|
Fax No.: |
91-20-30516161 |
|
E-Mail : |
|
|
Website : |
|
|
|
|
|
Marketing Office : |
501,5th Floor, Aurus, Annexe 'A' Amrutwar Road, Worli Mumbai - 400018 India |
|
Tel. No.: |
91-22-30260500 |
|
E-Mail : |
|
|
|
|
|
Representative Office 1 : |
350 - 530 Kenaston Blvd, Winnipeg, MB, Canada R3N 1Z4 |
|
Tel. No.: |
+204 928-2030 |
|
Fax No.: |
+204 928-2040 |
|
E-Mail : |
|
|
|
|
|
Representative Office 2 : |
0303, The Manor, 91 Nguyen Huu Canh, Binh Thanh Dist, Ho
Chi Minh City, |
|
Tel. No.: |
+ 841 656016915 |
|
E-Mail : |
|
|
|
|
|
Overseas Office: |
SAVAPHARM
LLC
3A, bldg.1, Zvezdniy Parkway Moscow - 129085 E-Mail: sales@savaglobal.com |
DIRECTORS
As on 27.06.2011
|
Name : |
Mr. Vinod Jadhav |
|
Designation : |
Director |
|
Address : |
B-3/504, Lunkad Colonnade, Viman Nagar, Pune – 411014, Maharashtra,
India |
|
Date of Birth/Age : |
21.02.1972 |
|
Date of Appointment : |
10.02.2010 |
|
DIN No.: |
00022790 |
|
|
|
|
Name : |
Mr. Suvarna Jadhav |
|
Designation : |
Director |
|
Address : |
B-3/504, Lunkad Colonnade, Viman Nagar, Pune – 411014, Maharashtra,
India |
|
Date of Birth/Age : |
14.04.1979 |
|
Date of Appointment : |
10.02.2010 |
|
DIN No.: |
00022798 |
|
|
|
|
Name : |
Mr. Shailesh Shah |
|
Designation : |
Director |
|
Address : |
SR 1047/B-1 F.No. 464/B1, Flat No.1, Gokhale Road, Pune – 411005,
Maharashtra, India |
|
Date of Birth/Age : |
21.10.1950 |
|
Date of Appointment : |
10.02.2010 |
|
DIN No.: |
00181435 |
|
|
|
KEY EXECUTIVES
|
Name : |
Mr. Bhuvaneswari S |
|
Designation : |
Secretary |
|
Address : |
SNo.03 Vasuniwas, Yogeshwar Society, Vadaonsheri, Pune -411014,
Maharashtra, India |
|
Date of Birth/Age : |
16.12.1981 |
|
Date of Appointment : |
16.05.2011 |
|
|
|
|
Name : |
Mr. Adam Patel |
|
Designation : |
Manager in Finance and Accountant |
MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN
As on 27.06.2011
|
Names of Shareholders |
|
No. of Shares |
|
Shanta
Ramachandra Jadhav |
|
10 |
|
Renu Anjanikar |
|
1010 |
|
Kusum Shinde |
|
10 |
|
Raju Shinde |
|
410 |
|
Deepak Shinde |
|
210 |
|
Anagha Pharma
Private Limited, India |
|
393850 |
|
Vishal Jadhav |
|
550 |
|
Bharati
Chandanshive |
|
400 |
|
Tushar Kokane |
|
500 |
|
Namrata Kand |
|
250 |
|
Vijay Pawar |
|
210 |
|
Vrushali Rasal |
|
200 |
|
Umesh Powar |
|
200 |
|
Mandakini Jagtap |
|
200 |
|
Salama Sayyad |
|
200 |
|
Ashwini Shinde |
|
290 |
|
Geetha Shetty |
|
300 |
|
Roopali Shinde |
|
200 |
|
Vaishali Kashid |
|
100 |
|
Maruti Rajiwade |
|
100 |
|
Sarika Shayam Sunder |
|
200 |
|
Nilesh Dhotre |
|
100 |
|
Salma Shaikh |
|
100 |
|
G.Thirumal Marugan |
|
100 |
|
Sarjerao Shinde |
|
90 |
|
Nilesh Lashkare |
|
50 |
|
Mahesh Dhotre |
|
50 |
|
Sagar Lashkare |
|
50 |
|
Santhosh Mogare |
|
50 |
|
Chandrakant
Salunke |
|
50 |
|
Bhimsen Renuse |
|
50 |
|
Jagannath Konnur |
|
50 |
|
Naresh Shinde |
|
50 |
|
Sujata Bhosale |
|
30 |
|
Atul Dhotre |
|
20 |
|
Hanmant Gaikwad |
|
81150 |
|
Vaishali Gaikwad |
|
59510 |
|
Priyanka Rajpurohit |
|
100 |
|
|
|
|
|
Total |
|
541000 |
As on 28.03.2012
|
Names of Allottees |
|
No. of Shares |
|
Anagha Pharma
Private Limited, India |
|
450000 |
|
|
|
|
|
Total |
|
450000 |
Equity Share Break up (Percentage of Total Equity)
As on 27.06.2011
|
Category |
Percentage |
|
Bodies corporate |
72.80 |
|
Directors or relatives of Directors |
0.36 |
|
Other top fifty shareholders |
26.84 |
|
Total |
100.00 |
BUSINESS DETAILS
|
Line of Business : |
Manufacturer of Pharmaceutical products,
ayurvedic medicines, allopathic medicines. |
|
|
|
|
|
|
Products : |
ITC No: |
Product
Description |
|
|
30049099 |
Cefmira 1gm Inj |
|
|
25070021 |
Cofrem 100ml Syrup |
|
|
30049099 |
Fazidim 1gm Inj |
|
|
30049099 |
Karocef 1gm Inj |
|
|
30049099 |
Mirapim 1gm Inj |
|
|
30045090 |
Mustang CT 100 mg 7 Flavours Tablets |
|
|
30043190 |
Salmibact 1gm/500mg Inj |
|
|
30045090 |
Savitra 20mg 10 Tab |
|
|
25070021 |
Tefroliv Forte Tablets 3 X 20'S |
|
|
30045090 |
Visiocare Ointment 2MG/GM 3.5 gm |
GENERAL INFORMATION
|
No. of Employees : |
Not Divulged |
|||||||||
|
|
|
|||||||||
|
Bankers : |
Not Divulged |
|||||||||
|
|
|
|||||||||
|
Facilities : |
(Rs. in Millions)
|
|
|
|
|
Banking
Relations : |
-- |
|
|
|
|
Auditors : |
|
|
Name : |
Ajay P Rander Chartered Accountant |
|
Address : |
344/1 Office No.4 and 5, Near Modi Ganpati Narayan, Peth, Pune –
411030, Maharashtra, India |
|
PAN.: |
AAZPR5900K |
|
|
|
|
Wholly Owned
Subsidiary Company: |
·
Sava Medica (Singapore) Pte. Limited |
|
|
|
|
Associates: |
·
Sava Trading FZC ·
Sava Infotech Private Limited ·
Sava Pharma
Limited ·
Anagha Pharma Private Limited ·
Biodeal Laboratories Private Limited |
CAPITAL STRUCTURE
As on 27.06.2011
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
1000000 |
Equity Shares |
Rs.100/- each |
Rs.100.000 Millions |
|
|
|
|
|
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
991000 |
Equity Shares |
Rs.100/-
each |
Rs.99.100
Millions |
|
|
|
|
|
As on 31.03.2011
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
550000 |
Equity Shares |
Rs.100/- each |
Rs.55.000 Millions |
|
|
|
|
|
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
541000 |
Equity Shares |
Rs.100/-
each |
Rs.54.100
Millions |
|
|
|
|
|
FINANCIAL DATA
[all figures are
in Rupees Millions]
ABRIDGED BALANCE
SHEET
|
SOURCES OF FUNDS |
|
|
31.03.2011 |
|
|
SHAREHOLDERS FUNDS |
|
|
|
|
|
1] Share Capital |
|
|
54.100 |
|
|
2] Share Application Money |
|
|
0.000 |
|
|
3] Reserves & Surplus |
|
|
1.414 |
|
|
4] (Accumulated Losses) |
|
|
0.000 |
|
|
NETWORTH |
|
|
55.514 |
|
|
LOAN FUNDS |
|
|
|
|
|
1] Secured Loans |
|
|
1.124 |
|
|
2] Unsecured Loans |
|
|
0.000 |
|
|
TOTAL BORROWING |
|
|
1.124 |
|
|
DEFERRED TAX LIABILITIES |
|
|
0.141 |
|
|
|
|
|
|
|
|
TOTAL |
|
|
56.779 |
|
|
|
|
|
|
|
|
APPLICATION OF FUNDS |
|
|
|
|
|
|
|
|
|
|
|
FIXED ASSETS [Net Block] |
|
|
7.276 |
|
|
Capital work-in-progress |
|
|
0.552 |
|
|
|
|
|
|
|
|
INVESTMENT |
|
|
0.071 |
|
|
DEFERREX TAX ASSETS |
|
|
0.000 |
|
|
|
|
|
|
|
|
CURRENT ASSETS, LOANS & ADVANCES |
|
|
|
|
|
|
Inventories |
|
|
0.000 |
|
|
Sundry Debtors |
|
|
0.000 |
|
|
Cash & Bank Balances |
|
|
172.058 |
|
|
Other Current Assets |
|
|
0.322 |
|
|
Loans & Advances |
|
|
253.654 |
|
Total
Current Assets |
|
|
426.034 |
|
|
Less : CURRENT
LIABILITIES & PROVISIONS |
|
|
|
|
|
|
Sundry Creditors |
|
|
2.616 |
|
|
Other Current Liabilities |
|
|
374.779 |
|
|
Provisions |
|
|
0.790 |
|
Total
Current Liabilities |
|
|
378.185 |
|
|
Net Current Assets |
|
|
47.849 |
|
|
|
|
|
|
|
|
MISCELLANEOUS EXPENSES |
|
|
1.031 |
|
|
|
|
|
|
|
|
TOTAL |
|
|
56.779 |
|
PROFIT & LOSS
ACCOUNT
|
|
PARTICULARS |
|
|
31.03.2011 |
|
|
|
SALES |
|
|
|
|
|
|
|
Income |
|
|
32.025 |
|
|
|
Other Income |
|
|
0.864 |
|
|
|
TOTAL (A) |
|
|
32.889 |
|
|
|
|
|
|
|
|
Less |
EXPENSES |
|
|
|
|
|
|
|
Consumption material changes inventories |
|
|
23.947 |
|
|
|
Manufacturing service costs |
|
|
1.763 |
|
|
|
Employee related expenses |
|
|
2.059 |
|
|
|
Administrative selling other expenses |
|
|
4.220 |
|
|
|
TOTAL (B) |
|
|
31.989 |
|
|
|
|
|
|
|
|
Less |
PROFIT
BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION (A-B) (C) |
|
|
0.900 |
|
|
|
|
|
|
|
|
|
Less |
FINANCIAL
EXPENSES (D) |
|
|
0.069 |
|
|
|
|
|
|
|
|
|
|
PROFIT
BEFORE TAX, DEPRECIATION AND AMORTISATION (C-D) (E) |
|
|
0.831 |
|
|
|
|
|
|
|
|
|
Less/ Add |
DEPRECIATION/
AMORTISATION (F) |
|
|
0.557 |
|
|
|
|
|
|
|
|
|
|
PROFIT BEFORE
TAX (E-F) (G) |
|
|
0.274 |
|
|
|
|
|
|
|
|
|
Less |
TAX (I) |
|
|
0.192 |
|
|
|
|
|
|
|
|
|
|
PROFIT AFTER TAX
(G-I) (J) |
|
|
0.082 |
|
|
|
|
|
|
|
|
|
|
Earnings Per
Share (Rs.) |
|
|
0.54 |
|
KEY RATIOS
|
PARTICULARS |
|
|
|
31.03.2011 |
|
PAT / Total Income |
(%) |
|
|
0.25 |
|
|
|
|
|
|
|
Net Profit Margin (PBT/Sales) |
(%) |
|
|
0.86 |
|
|
|
|
|
|
|
Return on Total Assets (PBT/Total Assets} |
(%) |
|
|
0.06 |
|
|
|
|
|
|
|
Return on Investment (ROI) (PBT/Networth) |
|
|
|
0.00 |
|
|
|
|
|
|
|
Debt Equity Ratio (Total Liability/Networth) |
|
|
|
6.83 |
|
|
|
|
|
|
|
Current Ratio (Current Asset/Current Liability) |
|
|
|
1.13 |
LOCAL AGENCY FURTHER INFORMATION
Sundry Creditors Details:
Rs. In Millions
|
Particulars |
|
|
31.03.2011 |
|
Sundry Creditors |
|
|
|
|
Micro, Small and Medium Enterprise and
others |
|
|
0.000 |
|
Others |
|
|
2.616 |
|
Total |
|
|
2.616 |
|
Sr. No. |
Check List by Info Agents |
Available in
Report (Yes / No) |
|
1] |
Year of Establishment |
Yes |
|
2] |
Locality of the firm |
Yes |
|
3] |
Constitutions of the firm |
Yes |
|
4] |
Premises details |
No |
|
5] |
Type of Business |
Yes |
|
6] |
Line of Business |
Yes |
|
7] |
Promoter's background |
Yes |
|
8] |
No. of employees |
No |
|
9] |
Name of person contacted |
Yes |
|
10] |
Designation of contact
person |
Yes |
|
11] |
Turnover of firm for last
one year |
Yes |
|
12] |
Profitability for last
one year |
Yes |
|
13] |
Reasons for variation
<> 20% |
-- |
|
14] |
Estimation for coming
financial year |
No |
|
15] |
Capital in the business |
Yes |
|
16] |
Details of sister
concerns |
Yes |
|
17] |
Major suppliers |
No |
|
18] |
Major customers |
No |
|
19] |
Payments terms |
No |
|
20] |
Export / Import details
(if applicable) |
No |
|
21] |
Market information |
-- |
|
22] |
Litigations that the firm
/ promoter involved in |
-- |
|
23] |
Banking Details |
Yes |
|
24] |
Banking facility details |
Yes |
|
25] |
Conduct of the banking
account |
-- |
|
26] |
Buyer visit details |
-- |
|
27] |
Financials, if provided |
Yes |
|
28] |
Incorporation details, if
applicable |
Yes |
|
29] |
Last accounts filed at
ROC |
Yes |
|
30] |
Major Shareholders, if
available |
Yes |
|
31] |
PAN of
Proprietor/Partner/Director, if available |
No |
|
32] |
Passport No of Proprietor/Partner/Director,
if available |
No |
|
33] |
Voter ID No of
Proprietor/Partner/Director, if available |
No |
Note: Registered office of the company has been
shifted from 3rd Floor, Lalwani Plaza, Wing B, Sakorenagar CHs, Off
New Airport Road, Viman Nagar, Pune – 411014, Maharashtra, India to the present
address w.e.f. 26.11.2011.
AS PER WEBSITE DETAILS
COMPANY OVERVIEW
Esteemed
in 2003, they are committed to make life "SAVA" with their range of
healthcare products and services that are benchmark of 'Superlative Quality,
Enviable Economy'. Built on the sturdy pillars of financial solidarity,
stability, reliability, operational expertise, infrastructure, technology and
revolutionary business strategy and execution, the SAVA Group is worth US $50
million and growing with CAGR of 150%, nearly 10 times that of the average
pharmaceutical industry. The SAVA Group has attained an iconic stature in
pharmaceutical arena making the lives of millions of people feel good.
Their
well-known generic manufacturing plant located, in Surendranagar near Ahmedabad
in India, helps SAVA attain its magnanimous capability of "curative
power" by producing over 500 products in what stands as one of the widest
range of therapeutic categories in India. The SAVA group of companies
constitute independent and well-established entities in manufacturing,
marketing, retail and distribution to cover the entire value-chain in
pharmaceuticals. This along with strategically prominent marketing nodes the
world over, gives SAVA the edge to be self-sustained in effectively delivering
their vast range of products across various geographies. It also serves to
fulfill their commitment to deliver "beyond the maxim of care".
NEWS
Avesthagen floats
JV with Sava Medica to sell nutraceuticals
Bangalore, Oct. 31:
Biotech major
Avesthagen has partnered with Sava Medica Limited of Pune to float 50:50 joint
venture subsidiary — Dhanvantari Botanicals — to market a range of nutraceuticals
products in the US and BRIS (Brazil, Russia, India, and South Africa)
countries.
Through this joint
venture, Avesthagen grants and Sava Medica earns marketing rights for
Avesthagen's seven over-the-counter (OTC)-formulated tablet (including
child-convenient dose such as fast-dissolving tablet), capsule and liquid forms
for medical use.
Dr Viloo
Morawala-Patell, founder and CMD of Avesthagen Limited, said, “The company so
far has achieved convergence between food, pharma and population genetics. This
transaction is part of our strategy to bring proprietary products, diagnostics,
functional foods, and biological therapeutics focusing on metabolic disorders,
cancer and neuro-degenerative disorders to consumers through partnerships.”
“Under the terms
of the deal, Avesthagen will receive upfront payments and a 15 per cent royalty
on product net sales in the US and BRIS countries,” she added.
Dhanvantari
Botanical's products basket includes 11 OTC brands positioned for the wellness
and nutraceutical markets. They are AmlaPure, Ashwagandha, BosWell, Gymnema,
ThinkWell, Tribulus, Triphala, TriplaLax, WinterWell, XanoMax, and GojiMax and
few qualified bulk ingredients.
Mr Vinod Jadhav,
founder and Managing Director of Sava Medica, commenting on the deal said: “We
at Sava Medica look forward to this strategic partnership to promote wellness
and nutrition products in BRIS and the US.
“With our strong
sales and marketing force, and vital manufacturing and research capabilities
in-built in our geosystem, we are now well-positioned to capture a significant
share of the global healthcare market with such definitive value-added
products.”
CMT REPORT (Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts,
1] INFORMATION ON
DESIGNATED PARTY
No records exist designating subject or any of its beneficial owners,
controlling shareholders or senior officers as terrorist or terrorist
organization or whom notice had been received that all financial transactions
involving their assets have been blocked or convicted, found guilty or against
whom a judgement or order had been entered in a proceedings for violating
money-laundering, anti-corruption or bribery or international economic or
anti-terrorism sanction laws or whose assets were seized, blocked, frozen or
ordered forfeited for violation of money laundering or international
anti-terrorism laws.
2] Court Declaration :
No records exist to suggest that subject is
or was the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper
payments to government officials for engaging in prohibited transactions or
with designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction registered
against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or
investigation registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No
available information exist that suggest that subject or any of its principals
have been formally charged or convicted by a competent governmental authority
for any financial crime or under any formal investigation by a competent
government authority for any violation of anti-corruption laws or international
anti-money laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling shareholders,
director, officer or employee of the company is a government official or a
family member or close business associate of a Government official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on Corporate
Governance to identify management and governance. These factors often have been
predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws,
regulations or policies that prohibit, restrict or otherwise affect the terms
and conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.55.76 |
|
|
1 |
Rs.86.79 |
|
Euro |
1 |
Rs.67.43 |
INFORMATION DETAILS
|
Information Gathered
by : |
SBA |
|
|
|
|
Report Prepared
by : |
KVT |
SCORE & RATING EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
2 |
|
PAID-UP CAPITAL |
1~10 |
4 |
|
OPERATING SCALE |
1~10 |
3 |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
3 |
|
--PROFITABILIRY |
1~10 |
2 |
|
--LIQUIDITY |
1~10 |
3 |
|
--LEVERAGE |
1~10 |
3 |
|
--RESERVES |
1~10 |
2 |
|
--CREDIT LINES |
1~10 |
4 |
|
--MARGINS |
-5~5 |
-- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
NO |
|
--AFFILIATION |
YES/NO |
YES |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
TOTAL |
|
26 |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
- |
NB |
New Business |
- |
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.